JeanMarie Guenot is very successful and accomplished business leader and is a role model. She has worked for over 20 years in the pharmaceutical and biotechnology industry. She is the President and CEO of Amphivena Therapeutics, a company which is developing breakthrough bi-functional antibody medicine for hematologic malignancies. Guenot has worked at all levels in large enterprises in the pharmaceutical, business development, commercial and corporate development, project and alliance management and venture capital.
JeanMarie Guenot began her glittering entrepreneurial career at the Atlas Venture where she started life science firms and managed venture capital investments. She worked as a scientist in Preclinical R&D at the Hoffman-La Roche. While working at the Hoffman-La Roche, she discovered and developed drugs for metabolic diseases, autoimmune diseases, oncology, and inflammation. She has studied physical and medicinal chemistry. Dr. Guenot has specialized in X-Ray NMR refinement, semi-empirical methods in molecular dynamics, quantum mechanical systems, and protein structure prediction. According to JeanmarieGuenot.com she got her Master of Business Administration degree at the University of Pennsylvania. After that, she did her Ph.D. at the University of California.
According to Crunchbase, Guenot founded SKS Ocular before starting to work for Amphivena Therapeutics. SKS was a pharmaceutical company which focused on the development of new therapeutics for significant unmet medical needs. It specialized on dry AMD, molecular degeneration, constant release of ocular drug delivery technologies, therapeutics for glaucoma and ocular inflammation therapeutics.
At Hoffman-La Roche in Shanghai and Basel, Guenot was a business advisor. She was also the Vice President of Corporate together with Business Development at the PDL BioPharma. When she was working for BioPharma, she led licensing, alliance management, mergers and acquisitions and commercial portfolios. JeanMarie was also involved in the Biogen Idec-PDL development and collaboration for commercialization. This included three Phase-2 cancer together with autoimmune disease drug patients. It was a $800million transaction that included a $100 million equity investment n PDL as well as therapeutic candidates.